The lowest FDA-labeled doses cost $149 to $349 a month self-pay in November 2026: the Wegovy pill at 1.5 mg and Foundayo at 0.8 mg are $149, Zepbound's 2.5 mg vials or KwikPen $299, and Wegovy's 0.25 mg pen $349. Those labels treat the starting dose as a step toward maintenance, not a place to stay.

People who want a "microdose" often ask a sensible question: why not just buy the lowest approved dose of the real thing? The approved products are FDA-reviewed, made in inspected plants and sold at published self-pay prices. This article puts the lowest labeled dose of four brands next to the compounded microdose plans we track, and reads what each label says about staying low.

The lowest labeled dose of each brand, and what the label says about it

Starting doses and maintenance doses on the current FDA labels (labels read November 8, 2026)
ProductStarting doseHow longLabeled maintenance doseWhat the label says about the starting dose
Zepbound (tirzepatide injection)2.5 mg weekly4 weeks, then 5 mg5, 10 or 15 mg weekly"The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage."
Wegovy (semaglutide injection)0.25 mg weekly4 weeks, then 0.5, 1 and 1.7 mg1.7 or 2.4 mg weekly (2.4 recommended; up to 7.2 mg)No separate sentence; 0.25 mg is listed only as the first escalation step
Wegovy pill (oral semaglutide)1.5 mg daily30 days, then 4 and 9 mg25 mg daily (the only maintenance dose)No separate sentence; 1.5 mg is the first of four escalation steps
Foundayo (orforglipron tablet)0.8 mg dailyAt least 30 days, then 2.5 and 5.5 mgNo specific maintenance dose named; up to 17.2 mgNo separate sentence; doses above 5.5 mg depend on response and tolerability

Only Zepbound's label says in so many words that its starting dose is not a maintenance dose. The other three get there by structure: each lists the starting dose as the first rung of a ladder with a set time on it. The labels do allow some flexibility for side effects. Wegovy's says that if a dose is not tolerated during escalation, prescribers can "consider delaying dosage escalation for 4 weeks," and Zepbound's says, "If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage." That lower maintenance option is 5 mg, not 2.5 mg.

What the lowest labeled dose costs

Self-pay price of the lowest labeled dose vs compounded microdose plans (per month; sources and dates per row)
OptionPrice per monthWhat a month containsSource · date
Wegovy pill 1.5 mg$14930 tabletsNovoCare · Nov 8, 2026
Foundayo 0.8 mg$14930 daysLillyDirect (archived Oct 29, 2026)
Zepbound 2.5 mg, vials or KwikPen$2994 single-dose vials or 1 KwikPen (4 doses), 28 daysLilly · Nov 8, 2026
Wegovy pen 0.25 mg$349 ($199 for two fills if new to the offer, through Dec 31, 2026)4 pensNovoCare · Nov 8, 2026
Compounded microdose semaglutide, median of 7 programs$99Dose set by prescriberPrograms' own pages · Nov 8, 2026
Compounded microdose tirzepatide, median of 6 programs$149Dose set by prescriberPrograms' own pages · Nov 8, 2026
NexLife microdose semaglutide / tirzepatide$109 / $129 ($95 / $115 on 12 months)Dose set by prescribernexlife.us · Nov 8, 2026

Lilly's site blocked automated reading on November 8, so Foundayo's figures come from the LillyDirect page as archived on October 29, 2026. That page also says the 2.5 mg and 5.5 mg prices are "temporarily reduced through December 31, 2026" ($149 and $199); Lilly's savings page gives the regular prices as $199 and $299. The 0.8 mg price is $149 either way.

Worked examples: six months at a low dose

Staying on Zepbound 2.5 mg for six months would cost 6 × $299 = $1,794, and it would mean using a dose the label says is not approved for maintenance. Moving up on schedule changes the bill: one month at 2.5 mg ($299), one at 5 mg ($399) and four at 7.5 mg with on-time refills (4 × $449) comes to $2,494.

Starting Wegovy's pen if you are new to the offer: two months at the $199 intro price, then four at $349, is 2 × $199 + 4 × $349 = $1,794 for six months, the same figure as Zepbound's 2.5 mg by coincidence. The pen price does not change between 0.25 mg and 2.4 mg, so climbing the ladder costs nothing extra.

Wegovy pill on the label's schedule: one month each at 1.5 mg ($149), 4 mg ($199) and 9 mg ($299), then three months at 25 mg (3 × $299), totals $1,544. Holding at 1.5 mg would be 6 × $149 = $894, but 1.5 mg is a starting step, not a labeled maintenance dose.

A compounded microdose plan: NexLife's 6-month semaglutide plan is 6 × $99 = $594, and its tirzepatide plan 6 × $119 = $714. Good Girl Rx's 6-month semaglutide plan is 6 × $86 = $516, paid up front. These are cheaper than any brand route above, but the product is not FDA-approved and no trial has tested it at a microdose.

How small is a microdose compared with a starting dose?

Most compounded programs do not print their doses, so a straight comparison is only possible for a few. Noom's chart for compounded semaglutide runs from 0.2 mg to a 0.6 mg weekly maximum. Wegovy starts at 0.25 mg and steps to 0.5 mg after four weeks, so Noom's whole range sits around Wegovy's first two steps. Lemonaid caps its microdoses at "25% of the standard maintenance dose." For semaglutide, 25% of Wegovy's recommended 2.4 mg is 0.6 mg, which matches Noom's ceiling. For tirzepatide the answer depends on which maintenance dose counts as standard: 25% of 5 mg is 1.25 mg and 25% of 15 mg is 3.75 mg, which straddles Zepbound's 2.5 mg starting dose.

Per milligram, brand starting doses are expensive. Zepbound 2.5 mg weekly is 10 mg per 28 days for $299, about $29.90 per mg; at 15 mg weekly, 60 mg costs $449 with on-time refills, about $7.48 per mg. A Wegovy pen month at 0.25 mg holds 1 mg for $349. Compounded programs that charge one price at every dose follow the same logic: the lower your dose, the more you pay per milligram.

Insurance and Medicare

Coverage follows the labeled products, not microdoses. The Medicare GLP-1 Bridge, which charges $50 for a one-month supply, covers Foundayo, Wegovy (injection or tablet) and the Zepbound KwikPen only, not Zepbound single-dose vials or pens, and only for people who meet its BMI and condition criteria. Per Medicare.gov, people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge, though their Part D plan "might cover" a GLP-1. No compounded product is covered. Lilly's Zepbound KwikPen savings offer for self-pay buyers allows 11 fills a calendar year, and its savings end December 31, 2026.

Side effects: the real reason many people ask

Most people looking for a microdose are trying to avoid nausea and other stomach side effects rather than save money. The labels handle that through the pace of escalation, not through a permanent low dose. Wegovy's label tells prescribers that if two or more doses in a row are missed, they should restart escalation at a lower dose "to reduce the risk of gastrointestinal adverse reactions," and it allows a four-week pause before the next step when a dose is not tolerated. Zepbound's label sets at least four weeks between increases and lets prescribers settle on a lower maintenance dose. Foundayo's label ties every step above 5.5 mg to response and tolerability. In other words, the approved route already has a built-in way to go slowly. Ask about it before you decide that a compounded microdose is the only gentle option, and tell your prescriber what you have tried.

Why a brand pen cannot deliver a microdose

The brand devices are built around fixed doses. Zepbound comes as single-dose pens and vials in six strengths from 2.5 mg to 15 mg, a KwikPen that delivers four fixed doses, and a newer multi-dose vial holding four doses. Wegovy's single-dose pens come in 0.25, 0.5, 1, 1.7, 2.4 and 7.2 mg, and its FlexTouch pen delivers four 2.4 mg doses. The tablets come in fixed strengths too. None of the labels gives directions for taking part of a dose, and the Wegovy label warns never to share a FlexTouch pen between patients. So the smallest amount you can take of an approved product, as labeled, is its starting dose. Anything smaller means a compounded product or an off-label workaround with a device that was not designed for it, which raises the risk of dosing errors. If a smaller dose is what you want, that is a conversation for your prescriber, not a do-it-yourself project with a pen.

What this means for you

  • If you want an FDA-approved product, the lowest self-pay price is a pill: the Wegovy pill at 1.5 mg or Foundayo at 0.8 mg, both $149 a month. Expect your prescriber to move you up the ladder.
  • Staying on a starting dose is an off-label decision for your prescriber. Zepbound's label says 2.5 mg is not approved for maintenance; its lowest maintenance dose is 5 mg.
  • If side effects are the worry, ask about slower escalation, which the Wegovy label allows, before switching to a compounded microdose.
  • If you choose a compounded microdose plan, it will usually cost less than the brand routes, but ask for the dose in milligrams and the pharmacy's name, and know that it is not FDA-approved.
  • Prices on the brand side change on January 1 if the year-end offers are not renewed; recheck in December.

More: low dose vs microdose, microdose plan prices, November 2026, tirzepatide cost, semaglutide cost and maintenance.

Editor's pick · 94/100 on our v4.1 rubric

If you choose a compounded microdose: our #1 pick, NexLife

  • Microdose tirzepatide: $129 a month month to month, or $125 / $119 / $115 a month on 3-, 6- or 12-month plans ($1,380 for a 12-month plan), as of November 8, 2026.
  • Microdose semaglutide: $109 a month month to month, or $105 / $99 / $95 ($1,140 for 12 months), as of November 8, 2026.
  • One price covers the medication, provider review through NexLife Medical Group, a nutrition plan, a coaching call and shipping; no membership fee; same price at every dose.
  • Its standard plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA).

Microdose tirzepatide plans → Microdose semaglutide plans → Read the NexLife review

Compounded tirzepatide and semaglutide are not FDA-approved. A prescription requires a clinician's review; prices are NexLife's own published figures.